Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy

Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategy

Aberrant activity of the cysteine protease Cathepsin S (CTSS) has been implicated across a wide range of pathologies. Notably in cancer, CTSS has been shown to promote tumour progression, primarily through facilitating invasion and migration of tumour cells and augmenting angiogenesis. Whilst an att...

Full description

Bibliographic Details
Main Authors: P. Smyth, L. Ferguson, J. F. Burrows, R. E. Burden, S. R. Tracey, Ú. M. Herron, M. Kovaleva, R. Williams, A. J. Porter, D. B. Longley, C. J. Barelle, C. J. Scott
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
therapeutic
cancer
inhibitor
vNAR
cathepsin
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1296567/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1296567/full

Similar Items